• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Finch Therapeutics Group Inc.

    2/14/22 3:46:40 PM ET
    $FNCH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $FNCH alert in real time by email
    SC 13G 1 ftg-sc13g_12312021.htm SCHEDULE 13G


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

    SCHEDULE 13G
    (Rule 13d-102)

    INFORMATION TO BE INCLUDED
    IN STATEMENTS FILED PURSUANT
    TO RULES 13d-1(b), (c), AND
    (d) AND AMENDMENTS THERETO
    FILED PURSUANT TO RULE 13d-2
    (AMENDMENT NO. )

    Finch Therapeutics Group, Inc.
    (Name of Issuer)
     
    Common Stock, $.001 par value
    (Title of Class of Securities)
     
    31773D101
    (CUSIP Number)
     
     December 31, 2021
    (Date of Event Which Requires Filing of this Statement)
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)
    X Rule 13d-1(c)
    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     

     

    CUSIP No. 31773D101
    Page 2 of 6 pages
       


    1
    NAMES OF REPORTING PERSONS
     
     
     
    Chidozie Ugwumba
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     United States
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
     
    3,500,000
     
     
     
     
    6
    SHARED VOTING POWER
     
     
     0
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
     
    3,500,000
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
     0
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     
    3,500,000
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
     7.37%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
     IN
     
     
     
     
     

    CUSIP No. 31773D101
    Page 3 of 6 pages
       

    Item 1(a). Name of Issuer:
     
    Finch Therapeutics Group, Inc.
     
    Item 1(b). Address of Issuer's Principal Executive Offices:
     
    200 Inner Belt Road, Suite 400, Somerville, Massachusetts 02143

    Item 2(a). Name of Person Filing:
     
    Chidozie Ugwumba

    Item 2(b). Address of Principal Business Office or, if none, Residence:
     
    c/o SymBiosis Capital Management, LLC, 609 SW 8th St., Suite 365, Bentonville, AR 72712

    Item 2(c). Citizenship:

     United States

    Item 2(d). Title of Class of Securities:

     Common Stock
     
    Item 2(e). CUSIP Number:
     
    31773D101


    CUSIP No. 31773D101
    Page 4 of 6 pages
       

    Item 3. If This Statement Is Filed Pursuant to Sections 240.13d-1(b) or
    240.13d-2(b) or (c), Check Whether the Person Filing Is a(n):

    Not applicable


    (a) ☐ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);


    (b) ☐ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);


    (c) ☐ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);


    (d) ☐ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);


    (e) ☐ Investment adviser in accordance with Section 240.13d-1(b)(1)(ii)(E);


    (f) ☐ Employee benefit plan or endowment fund in accordance with Section 240.13d-1(b)(1)(ii)(F);


    (g) ☐ Parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G);


    (h) ☐ Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);


    (i) ☐ Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);


    (j) ☐ A non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J);


    (k) ☐ Group, in accordance with Section 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____________________________ .
     
    Item 4. Ownership.


    (a)
    Amount beneficially owned: 

    3,500,000


    (b)
    Percent of class:

    7.37%


    (c) Number of shares as to which the person has:


    (i)
    Sole power to vote or to direct the vote:

    3,500,000


    (ii)
    Shared power to vote or to direct the vote:

    0

      (iii)
    Sole power to dispose or to direct the disposition of:

    3,500,000

      (iv)
    Shared power to dispose or to direct the disposition of:

    0
     

    The shares are directly held by SymBiosis, LLC.  Previously, the beneficial owner of these shares was Thomas Layton Walton, by virtue of his sole voting power and dispositive power through SymBiosis, LLC.  Although SymBiosis, LLC continues to hold these shares directly and Thomas Layton Walton continues to hold his pecuniary interest in these shares, the reporting person now exercises sole voting power and dispositive power through SymBiosis, LLC through a transition of that power to the reporting person (and not through a sale or other transfer of these shares).


    CUSIP No. 31773D101
    Page 5 of 6 pages
       

    Item 5. Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

    Not applicable

    Item 6.
    Ownership of More Than Five Percent on Behalf of Another Person.

    Not applicable

     
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

    Not applicable
     

    Item 8.
    Identification and Classification of Members of the Group.

    Not applicable
     

    Item 9.
    Notice of Dissolution of Group.

    Not applicable
     
     
    Item 10.
    Certification.
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
     


    CUSIP No. 31773D101
    Page 6 of 6 pages
       
    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated:  February 14, 2022
     
     

     
     

     /s/ Chidozie Ugwumba
       
    Name:  Chidozie Ugwumba
       
     
     
     
     

    Get the next $FNCH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FNCH

    DatePrice TargetRatingAnalyst
    8/9/2022$17.00Buy
    H.C. Wainwright
    More analyst ratings

    $FNCH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Finch Announces Delisting from Nasdaq and SEC Deregistration

      BOSTON, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (NASDAQ:FNCH) ("Finch" or the "Company"), a microbiome technology company with a portfolio of intellectual property and microbiome assets, today announced that it has provided notification to The Nasdaq Stock Market, LLC ("Nasdaq") of its intent to delist the Company's common stock, par value $0.001 per share (the "Common Stock"), from the Nasdaq Global Select Market. Finch expects to file a Form 25 (Notification of Removal from Listing) with the Securities and Exchange Commission (the "SEC") and Nasdaq relating to the delisting of its Common Stock on or about October 31, 2024. The removal of the Common Stock from Nas

      10/21/24 7:30:00 AM ET
      $FNCH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Finch Announces Reverse Stock Split of Common Stock

      BOSTON, June 09, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch", "Finch Therapeutics" or the "Company") (NASDAQ:FNCH), a microbiome technology company with a portfolio of intellectual property and microbiome assets, today announced it will effect a one-for-30 reverse stock split of its issued and outstanding common stock. Finch stockholders approved an amendment to its Amended and Restated Certificate of Incorporation to effect the reverse stock split at Finch's Annual Meeting of Stockholders held on June 8, 2023. The reverse stock split is intended to increase the per share trading price of Finch's common stock to enable Finch to satisfy the minimum price requirement for

      6/9/23 7:00:00 AM ET
      $FNCH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Finch Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates

      SOMERVILLE, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch", "Finch Therapeutics" or the "Company") (NASDAQ:FNCH), a microbiome technology company with a portfolio of intellectual property and microbiome assets, today reported first quarter 2023 financial results and provided business updates. "Finch has continued to execute on its strategy to advance its novel microbiome technology through partnerships and collaborations, highlighted by the recent investigator-sponsored clinical trial agreement with Brigham and Women's Hospital to evaluate CP101 for the treatment of ulcerative colitis and an amended license agreement with the University of Minnesota," said

      5/10/23 7:00:00 AM ET
      $FNCH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FNCH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Finch Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Finch Therapeutics with a rating of Buy and set a new price target of $17.00

      8/9/22 7:20:02 AM ET
      $FNCH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jefferies initiated coverage on Finch Therapeutics with a new price target

      Jefferies initiated coverage of Finch Therapeutics with a rating of Buy and set a new price target of $29.00

      4/13/21 7:45:43 AM ET
      $FNCH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Evercore ISI initiated coverage on Finch Therapeutics with a new price target

      Evercore ISI initiated coverage of Finch Therapeutics with a rating of Outperform and set a new price target of $34.00

      4/13/21 7:40:55 AM ET
      $FNCH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FNCH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Smisek Jeffery A gifted 767 shares, decreasing direct ownership by 2% to 17,870 units (SEC Form 4)

      4 - Finch Therapeutics Group, Inc. (0001733257) (Issuer)

      6/10/24 7:00:03 PM ET
      $FNCH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Smisek Jeffery A gifted 3,750 shares (SEC Form 4)

      4 - Finch Therapeutics Group, Inc. (0001733257) (Issuer)

      5/24/24 8:00:08 PM ET
      $FNCH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Smisek Jeffery A sold $21,246 worth of shares (8,242 units at $2.58), closing all direct ownership in the company (SEC Form 4)

      4 - Finch Therapeutics Group, Inc. (0001733257) (Issuer)

      3/29/24 4:15:21 PM ET
      $FNCH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FNCH
    SEC Filings

    See more
    • SEC Form 15-12G filed by Finch Therapeutics Group Inc.

      15-12G - Finch Therapeutics Group, Inc. (0001733257) (Filer)

      11/12/24 8:10:56 AM ET
      $FNCH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Finch Therapeutics Group Inc.

      EFFECT - Finch Therapeutics Group, Inc. (0001733257) (Filer)

      11/5/24 12:15:05 AM ET
      $FNCH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 POS filed by Finch Therapeutics Group Inc.

      S-8 POS - Finch Therapeutics Group, Inc. (0001733257) (Filer)

      11/1/24 8:02:57 AM ET
      $FNCH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FNCH
    Leadership Updates

    Live Leadership Updates

    See more
    • Finch Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates

      SOMERVILLE, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch", "Finch Therapeutics" or the "Company") (NASDAQ:FNCH), a microbiome technology company with a portfolio of intellectual property and microbiome assets, today reported first quarter 2023 financial results and provided business updates. "Finch has continued to execute on its strategy to advance its novel microbiome technology through partnerships and collaborations, highlighted by the recent investigator-sponsored clinical trial agreement with Brigham and Women's Hospital to evaluate CP101 for the treatment of ulcerative colitis and an amended license agreement with the University of Minnesota," said

      5/10/23 7:00:00 AM ET
      $FNCH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Finch Therapeutics Announces Executive Leadership Transitions

      Matthew P. Blischak, an experienced life sciences executive and intellectual property counsel, appointed as Chief Executive Officer effective May 16, 2023; Mark Smith, PhD, to complete his time as CEO effective May 15 Lance Thibault, Managing Director of Danforth Advisors, to serve as Chief Financial Officer effective May 16, 2023; Marc Blaustein to complete his time as Chief Operating Officer and principal financial officer effective May 15 SOMERVILLE, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch", "Finch Therapeutics" or the "Company") (NASDAQ:FNCH), a microbiome technology company with a portfolio of intellectual property and microbiome assets, toda

      4/25/23 4:05:00 PM ET
      $FNCH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Finch Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates

      SOMERVILLE, Mass., March 31, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (NASDAQ:FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today reported fourth quarter and full year 2021 financial results and provided business updates. "Finch achieved many significant milestones in 2021, including new clinical data readouts that support our lead product candidate, CP101, for the prevention of recurrent C. difficile infection and the advancement of our TAK-524 ulcerative colitis development program to Takeda for further development. F

      3/31/22 4:56:00 PM ET
      $FNCH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FNCH
    Financials

    Live finance-specific insights

    See more

    $FNCH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Finch Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results

      FDA lifted clinical hold on IND for CP101Enrollment in PRISM4 Phase 3 trial of CP101 in recurrent CDI expected to proceed in H2 2022$15 million drawn from new $55 million term debt facility Anticipated cash runway into Q2 2024Corporate update call today at 8am ET SOMERVILLE, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (NASDAQ:FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today provided a corporate update and reported financial results for the first quarter ended March 31, 2022. "Finch made several important

      5/16/22 7:00:00 AM ET
      $FNCH
      $HTGC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Investment Managers
      Finance
    • Finch Therapeutics to Host Corporate Update Conference Call and Webcast on May 16, 2022

      SOMERVILLE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (NASDAQ:FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today announced it will host a conference call and live webcast on Monday, May 16, 2022 at 8:00am ET to discuss updates to its development programs and other business highlights. The conference call can be accessed by dialing (833) 649-1186 (domestic) or (270) 823-1080 (international) and entering conference ID 8451806. The live webcast can be accessed by visiting the ‘Investors & News' section of

      5/9/22 8:22:29 AM ET
      $FNCH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Finch Therapeutics Group Inc.

      SC 13G - Finch Therapeutics Group, Inc. (0001733257) (Subject)

      12/13/23 5:20:28 PM ET
      $FNCH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Finch Therapeutics Group Inc.

      SC 13G - Finch Therapeutics Group, Inc. (0001733257) (Subject)

      2/14/22 3:59:49 PM ET
      $FNCH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Finch Therapeutics Group Inc.

      SC 13G - Finch Therapeutics Group, Inc. (0001733257) (Subject)

      2/14/22 3:46:40 PM ET
      $FNCH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care